Arbutus Biopharma Corp
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-33.5M | $-69.9M | $-72.8M | $-69.5M | $-76.2M | $-63.7M | $-153.7M | $-57.1M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $363.0K | $1.4M | $1.4M | $1.4M | $1.8M | $2.0M | $2.0M | $2.2M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $7.0M | $9.0M | $9.3M | $7.2M | $6.4M | $6.2M | $6.8M | $6.2M |
| Net Cash from Operating Activities | $-39.6M | $-64.9M | $-85.9M | $-35.4M | $-67.5M | $-51.4M | $-71.0M | $-67.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $182.0K | $1.0M | $512.0K | $809.0K | $229.0K | $589.0K | $1.1M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $15.6M | $22.9M | $50.8M | $-74.9M | $-12.7M | $-14.9M | $28.3M | $-4.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $5.7M | $52.0M | $30.6M | $31.8M | $137.2M | $86.7M | $37.5M | $55.6M |
| Net Change in Cash | $-18.3M | $10.0M | $-4.5M | $-78.5M | $57.0M | $20.5M | $-5.1M | $-17.4M |
| Free Cash Flow | $-39.6M | $-65.0M | $-86.9M | $-35.9M | $-68.3M | $-51.7M | $-71.6M | $-69.0M |